Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | AR | P10275 | 5/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | XBP1 | P17861 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL748468 | 0.88 | MAPT (0.77) | MAPTHPGDARKCNH2ALOX15 | |
| SCHEMBL23657770 | 0.88 | MAPT (1.00) | MAPTHPGDARKCNH2ALOX15 | |
| SCHEMBL2266490 | 0.85 | MAPT (0.72) | MAPTHPGDARKCNH2ALOX15 | |
| SCHEMBL2262726 | 0.84 | AR (1.00) | MAPTHPGDARKCNH2ALOX15 | |
| SCHEMBL2267108 | 0.84 | MAPT (0.74) | MAPTHPGDARKCNH2ALOX15 | |
| SCHEMBL2263144 | 0.83 | AR (0.64) | MAPTHPGDARKCNH2ALOX15 | |
| SCHEMBL2265103 | 0.83 | MAPT (0.69) | MAPTHPGDARKCNH2ALOX15 | |
| SCHEMBL2264270 | 0.83 | MAPT (0.69) | MAPTHPGDARKCNH2ALOX15 | |
| SCHEMBL2268102 | 0.83 | AR (0.64) | MAPTHPGDARKCNH2ALOX15 | |
| SCHEMBL18126711 | 0.82 | HTT (0.74) | MAPTHPGDARKCNH2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | claimed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | claimed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | MAPT 2987/4885HPGD 438/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.